product candidate target indication discovery IND
phase1 phase2 phase3 commercial rights

BN104 Menin AML, ALL WW


BN104 is a novel, potent and highly selective small molecule menin inhibitor for potential treatment of acute leukemias with rearranged mixed lineage leukemia (MLLr) gene. It showed optimized drug-like properties and excellent efficacy in MV4-11 xenograft mouse model. Furthermore, BN104 has low risk in corrected QT interval (QTc) prolongation given the fact that it is an extremely weak human ether-a-go-go related gene (hERG) inhibitor with IC50 of greater than 100 uM. To date, BN104 has demonstrated favorable toxicity profile in preliminary preclinical studies and is on track for IND filing in May.

BN105 PRMT5 Solid Tumors WW


BN105 is a novel MTAP cooperative PRMT5 inhibitor, for the treatment of multiple solid tumors. BN105 showed inhibition of SDMA and anti-proliferation activities in HCT116 MTAP-del cells over HCT116 MTAP-WT cells with excellent selectivity.